Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies

Prostate cancer, as one of the most prevalent malignancies in males, exhibits an approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events and mutations, including the accumulation of oncometabolites, underpin the genesis and progression of this cancer type. Despite gr...

Full description

Saved in:
Bibliographic Details
Published in:Cell communication and signaling 2024-01, Vol.22 (1), p.36-36, Article 36
Main Authors: Ambrosini, Giulia, Cordani, Marco, Zarrabi, Ali, Alcon-Rodriguez, Sergio, Sainz, Rosa M, Velasco, Guillermo, Gonzalez-Menendez, Pedro, Dando, Ilaria
Format: Article
Language:English
Subjects:
Androgens
Cancer
Cancer cells
Cancer stem cells (CSCs)
Cancer therapies
Care and treatment
Dehydrogenases
Development and progression
EMT
Enzymes
Epigenesis, Genetic
Epigenetic alterations
Epigenetic inheritance
Epigenetics
Genetic aspects
Health aspects
Humans
Male
Malignancy
Metabolic Enzymes
Metabolism
Metabolites
MicroRNAs
Mutation
Neoplasms - pathology
Neoplastic Stem Cells - pathology
Oncology, Experimental
Oncometabolites
Phosphorylation
Prostate cancer
Prostatic Neoplasms - genetics
Proteins
Review
Stem cells
Therapeutic targets
Transcription factors
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer, as one of the most prevalent malignancies in males, exhibits an approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events and mutations, including the accumulation of oncometabolites, underpin the genesis and progression of this cancer type. Despite growing research demonstrating the pivotal role of oncometabolites in supporting various cancers, including prostate cancer, the root causes of their accumulation, especially in the absence of enzymatic mutations, remain elusive. Consequently, identifying a tangible therapeutic target poses a formidable challenge. In this review, we aim to delve deeper into the implications of oncometabolite accumulation in prostate cancer. We center our focus on the consequential epigenetic alterations and impacts on cancer stem cells, with the ultimate goal of outlining novel therapeutic strategies.
ISSN:1478-811X
1478-811X
DOI:10.1186/s12964-023-01462-0